guest ::
| Home > Publications database > Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. > print |
| Home > Publications database > Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. > print |
| 001 | 178851 | ||
| 005 | 20240229143557.0 | ||
| 024 | 7 | _ | |a pmid:35173482 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8841298 |2 pmc |
| 024 | 7 | _ | |a DOI:10.2147/CMAR.S289544 |2 doi |
| 024 | 7 | _ | |a DOI:10.2147/CMAR.S289544 |2 doi |
| 024 | 7 | _ | |a altmetric:122669481 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00307 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Nemes, Karolina |b 0 |
| 245 | _ | _ | |a Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. |
| 260 | _ | _ | |a Albany, Auckland |c 2022 |b Dove Medical Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1645436941_26140 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Extracranial malignant rhabdoid tumors (extracranial MRT) are rare, highly aggressive malignancies affecting mainly infants and children younger than 3 years. Common anatomic sites comprise the kidneys (RTK - rhabdoid tumor of kidney) and other soft tissues (eMRT - extracranial, extrarenal malignant rhabdoid tumor). The genetic origin of these diseases is linked to biallelic pathogenic variants in the genes SMARCB1, or rarely SMARCA4, encoding subunits of the SWI/SNF chromatin-remodeling complex. Even if extracranial MRT seem to be quite homogeneous, recent epigenome analyses reveal a certain degree of epigenetic heterogeneity. Use of intensified therapies has modestly improved survival for extracranial MRT. Patients at standard risk profit from conventional therapies; most high-risk patients still experience a dismal course and often therapy resistance. Discoveries of clinical and molecular hallmarks and the exploration of experimental therapeutic approaches open exciting perspectives for clinical and molecularly stratified experimental treatment approaches. To ultimately improve the outcome of patients with extracranial MRTs, they need to be characterized and stratified clinically and molecularly. High-risk patients need novel therapeutic approaches including selective experimental agents in phase I/II clinical trials. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a RTK |2 Other |
| 650 | _ | 7 | |a eMRT |2 Other |
| 650 | _ | 7 | |a experimental therapy |2 Other |
| 650 | _ | 7 | |a extracranial malignant rhabdoid tumors |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 700 | 1 | _ | |a Johann, Pascal D |0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |b 1 |u dkfz |
| 700 | 1 | _ | |a Tüchert, Stefanie |b 2 |
| 700 | 1 | _ | |a Melchior, Patrick |b 3 |
| 700 | 1 | _ | |a Vokuhl, Christian |b 4 |
| 700 | 1 | _ | |a Siebert, Reiner |b 5 |
| 700 | 1 | _ | |a Furtwängler, Rhoikos |0 0000-0002-1967-8343 |b 6 |
| 700 | 1 | _ | |a Frühwald, Michael C |b 7 |
| 773 | _ | _ | |a 10.2147/CMAR.S289544 |g Vol. 14 |0 PERI:(DE-600)2508013-1 |p 479-498 |t Cancer management and research |v 14 |y 2022 |x 1179-1322 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:178851 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version) |0 LIC:(DE-HGF)CCBYNCNV |2 V:(DE-HGF) |b DOAJ |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-02-04 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-02-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER MANAG RES : 2021 |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-10-14T20:45:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-10-14T20:45:45Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-10-14T20:45:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-10 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-10 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|